" /> Ibrutinib/Lenalidomide/Obinutuzumab/Polatuzumab Vedotin/Prednisone/Venetoclax Regimen - CISMeF





Preferred Label : Ibrutinib/Lenalidomide/Obinutuzumab/Polatuzumab Vedotin/Prednisone/Venetoclax Regimen;

NCIt synonyms : Venetoclax/Ibrutinib/Prednisone/Obinutuzumab/Revlimid Plus Polatuzumab Vedotin; Venetoclax-Ibrutinib-Prednisone-Obinutuzumab-Revlimid Plus Polatuzumab Vedotin; Imbruvica /Revlimid/Gazyva/Polivy/Prednisone/Venclexta; Ibrutinib/Lenalidomide/Obinutuzumab/Polatuzumab Vedotin/Prednisone/Venetoclax; Ibrutinib-Lenalidomide-Obinutuzumab-Polatuzumab Vedotin-Prednisone-Venetoclax; Ibrutinib-Lenalidomide-Obinutuzumab-Polatuzumab Vedotin-Prednisone-Venetoclax Regimen; ViPOR-P Regimen; Venetoclax/Ibrutinib/Prednisone/Obinutuzumab/Lenalidomide Plus Polatuzumab Vedotin; Venetoclax/Ibrutinib/Prednisone/Obinutuzumab/Lenalidomide Plus Polatuzumab Vedotin-piiq;

NCIt related terms : ViPOR-P;

NCIt definition : A regimen consisting of ibrutinib, lenalidomide, obinutuzumab, polatuzumab vedotin, prednisone, and venetoclax that may potentially be used in the treatment of certain B-cell lymphomas.;

Détails


Position du mot-clé dans l'(les) arborescence(s) : arborescence

Vous pouvez consulter :


Nous contacter.
28/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.